Related Experiment Video

Updated: Sep 8, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Endogenous risk factors in Parkinson's disease: dopamine and tetrahydroisoquinolines

Lucyna Antkiewicz-Michaluk1

  • 1Department of Biochemistry, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, PL 31-343 Kraków, Poland.

Polish Journal of Pharmacology
|July 18, 2003
PubMed

Insights

The exact causes of Parkinson's disease (PD) nigral cell death are unknown, but neurotoxins like MPTP and endogenous isoquinolines may play a role. Therapeutic strategies focus on antiapoptotic drugs to combat neurodegeneration.

Area of Science:

  • Neuroscience
  • Toxicology
  • Pathology

Background:

  • Parkinson's disease (PD) pathogenesis involves chronic nigral cell death with unknown mechanisms.
  • Exogenous and endogenous neurotoxins are implicated in nigrostriatal dopaminergic neuron loss.
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and isoquinoline derivatives (e.g., TIQ, salsolinol) are key neurotoxins.

Purpose of the Study:

  • To explore the role of neurotoxic substances in Parkinson's disease.
  • To investigate the mechanisms of nigral cell death in PD.
  • To identify potential therapeutic targets for PD.

Main Methods:

  • Review of literature on neurotoxins and Parkinson's disease.
  • Analysis of the neurochemical properties of MPTP and isoquinolines.
  • Discussion of excitotoxicity and apoptosis in PD pathogenesis.

Main Results:

  • MPTP is converted to MPP+, selectively killing dopaminergic neurons.
  • Endogenous isoquinolines share neurotoxic properties with MPTP.
  • Salsolinol and related compounds exhibit potent neurotoxic effects.

Conclusions:

  • Neurotoxic substances, both exogenous and endogenous, are significant factors in PD.
  • Apoptosis and excitotoxicity are likely contributors to PD progression.
  • Therapeutic strategies should target antiapoptotic mechanisms, including antioxidants and MAOB inhibitors.

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...